{"filing":{"accession_number":"0001140361-26-040181","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-18","primary_document":"ef20084000_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126040181/ef20084000_8k.htm"},"events":[{"id":36281,"run_id":33447,"accession_number":"0001140361-26-040181","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"PDS Biotechnology appointed three new directors—Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel—to its Board of Directors effective October 18, 2026, bringing substantial pharma industry experience in drug development, commercialization, and M\u0026A. The appointments occurred simultaneously with the resignation of four existing directors.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40642,"accession_number":"0001140361-26-040181","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of three new directors (Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel) to PDS Biotechnology's Board, effective October 18, 2026. While the section also reports the simultaneous resignation of four directors, the principal disclosed action centers on the appointments of the new directors with detailed biographical information and committee assignments. The new directors bring substantial pharma industry experience in drug development, commercialization, and M\u0026A, which is material to investors assessing the company's governance and strategic direction as it advances clinical trials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:01:46.464649+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40643,"accession_number":"0001140361-26-040181","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointments of three accomplished pharma executives—John Dawson CBE, Deborah Ramsdell, and Bruce Wendel—to PDS Biotech's Board of Directors effective October 18, 2026. While the section also mentions the resignations of four directors (Stephen Glover, Kamil Ali-Jackson, Gregory Freitag, and Otis Brawley), the press release's headline and primary focus emphasize the new appointments and their qualifications, making the appointment the principal disclosed action. The new directors bring significant industry experience in drug development, commercialization, and regulatory affairs relevant to the company's clinical pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:01:46.464649+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40642,"accession_number":"0001140361-26-040181","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of three new directors (Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel) to PDS Biotechnology's Board, effective October 18, 2026. While the section also reports the simultaneous resignation of four directors, the principal disclosed action centers on the appointments of the new directors with detailed biographical information and committee assignments. The new directors bring substantial pharma industry experience in drug development, commercialization, and M\u0026A, which is material to investors assessing the company's governance and strategic direction as it advances clinical trials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:01:46.464649+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-10-20"},{"id":40643,"accession_number":"0001140361-26-040181","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointments of three accomplished pharma executives—John Dawson CBE, Deborah Ramsdell, and Bruce Wendel—to PDS Biotech's Board of Directors effective October 18, 2026. While the section also mentions the resignations of four directors (Stephen Glover, Kamil Ali-Jackson, Gregory Freitag, and Otis Brawley), the press release's headline and primary focus emphasize the new appointments and their qualifications, making the appointment the principal disclosed action. The new directors bring significant industry experience in drug development, commercialization, and regulatory affairs relevant to the company's clinical pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:01:46.464649+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-10-20"}]}